CASI Pharmaceuticals, Inc. (CASI) EPS Estimated At $-0.03

March 20, 2018 - By reb123z

 CASI Pharmaceuticals, Inc. (CASI) EPS Estimated At $ 0.03
Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.53, from 1.67 in 2017Q2. It dived, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Moors Cabot has 0.01% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Northern Trust Corporation accumulated 31,034 shares. Wellington Shields And Limited Liability Company invested in 0.29% or 489,984 shares. Focused Wealth Mngmt stated it has 45 shares or 0% of all its holdings. Wells Fargo Mn holds 68 shares. Moreover, Jpmorgan Chase And has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Virtu Financial Limited Liability Company, New York-based fund reported 40,790 shares. Manatuck Hill Partners Lc holds 15,090 shares or 0.01% of its portfolio. Commercial Bank Of America De stated it has 1,144 shares or 0% of all its holdings. Everett Harris And Company Ca owns 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 10,002 shares. Raymond James Fincl Inc owns 55,135 shares for 0% of their portfolio. Renaissance Techs holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 112,900 shares. Deutsche Fincl Bank Ag owns 21 shares. California Public Employees Retirement System holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 136,518 shares. Vanguard Gru has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.03 EPS on March, 30.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 10.33% or $0.3315 during the last trading session, reaching $3.5415. About 172,238 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 20, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Thursday, October 29. The firm has “Buy” rating by Maxim Group given on Monday, August 14. On Thursday, September 22 the stock rating was initiated by Maxim Group with “Buy”. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) earned “Buy” rating by H.C. Wainwright on Tuesday, January 16.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $247.57 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.